ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Takeda starts trials of 3 COVID drugs in US with Amgen and AbbVie

Alliance looks to test existing treatments' potential against coronavirus

An alliance of 20 partners including Takeda Pharmaceutical will test multiple drug candidates in the coming months.   © Reuters

TOKYO -- Takeda Pharmaceutical has begun clinical trials on three potential treatments for COVID-19 as part of a research and development team that includes U.S. peers Amgen and AbbVie Japan's biggest drugmaker said Tuesday.

The COVID R&D Alliance is recruiting up to 1,500 patients for the trials, which will take place in the U.S. over a few months.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more